Culture Development Featured Articles

1. A New Cost Paradigm For CAR Cell Therapies? 6/12/2020

   Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.

2. FUJIFILM Diosynth Biotechnologies Chooses ambr250 System For Optimising Microbial Fermentation 9/16/2014

   TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, is pleased to announce that its ambr250 automated mini bioreactor system is being successfully used at leading Contract Development and Manufacturing Organisation, FUJIFILM Diosynth Biotechnologies, for optimising their microbial fermentations to accelerate scale-up production of protein-based therapeutics.

3. Synthetic Biologics And FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement In API Manufacturing Of SYN-004 For The Prevention Of C. difficile 8/28/2014

   Synthetic Biologics, Inc. , a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced recently confirmation of exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infections.

4. Scientists 'Snip' HIV From Cultured Human Cells 7/29/2014

   Scientists from Temple University reported that they have designed a new approach to remove HIV from human cells growing in culture through genome editing.

5. Stainless Steel Vial Filling System Developed For Use In Vaccine Facilities 7/17/2014

   TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, recently announced the development of a stainless steel version of the fill-it system, designed for safely dispensing biohazardous materials such as vaccine stocks.

6. FDA Approval Pushes Novartis Into 21st Century Vaccine Development 6/18/2014

   In 2009, the world experienced a global threat in the form of H1N1. Despite a prompt response to the need for a vaccine in the United States, it was still not available until six months later and not enough doses were even produced to cover all Americans. During the year-long battle with the deadly virus, the CDC estimates between 8,870 and 18,300 people died due to H1N1-related complications. In the world of influenza vaccine production using chicken eggs, the response experienced during the H1N1 outbreak is not uncommon. Is this the best our industry can do? Novartis says NO.

7. DiscoveRx's Assay IDs Safety Risks Better Than Animal Testing 5/21/2014

   New research reveals that DiscoveRx’s BioMAP Systems can identify significant drug safety aspects more effectively than animal testing. BioMAP Systems is a novel set of primary human cell and co-culture assays that model disease and pathway biology, which enables scientists to glean the safety and efficacy of drugs and chemicals.

8. GE Healthcare Launches Xuri™ IL-2 Growth Factor For The Reliable Activation And Expansion Of T-lymphocytes 5/14/2014

   Xuri™ IL-2 is a dedicated cell therapy ancillary product for the ex vivo cultivation of T-lymphocytes. Xuri IL-2’s defined level of biological activity removes the need for revalidation of each lot and strongly improves reproducibility, thereby minimizing process development time and improving scale out capacity.

9. Gallus BioPharmaceuticals Utilises ambr15 Micro Bioreactor To Rapidly Optimise Process Development Of Novel Antibodies And Biosimilars 4/29/2014

   TAP Biosystems, (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cellculture and fermentation systems for life science applications, is delighted to announce its ambr15 micro bioreactor system is being used at the leading US-based Contract Manufacturing Organisation (CMO), Gallus BioPharmaceuticals, LLC (“Gallus”) to optimise process development and clone selection of novel antibody therapeutics and biosimilars.

10. Irvine Scientific Announces Expansion Of BalanCD® Product Line To Serve Vaccine Market 4/14/2014

    Irvine Scientific is pleased to announce the launch of its BalanCD® MDCK cell culture medium, a next generation cell culture product responding to today’s requirements for media used in cell-based vaccine manufacturing. This new flagship product expands Irvine Scientific’s current BalanCD product portfolio of animal component-free and chemically-defined media with the addition of a new purpose-built product.